L, W., JK, F., B, Z., ZH, L., L, G., ML, Y., . . . SQ, C. (2026). Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy. The oncologist, 31(4), . https://doi.org/10.1093/oncolo/oyag054
Chicago Style (17th ed.) CitationL, Wang, et al. "Optimal Duration of Adjuvant Targeted-immunotherapy in Patients with Initially Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Successful Conversion Therapy." The Oncologist 31, no. 4 (2026). https://doi.org/10.1093/oncolo/oyag054.
MLA (9th ed.) CitationL, Wang, et al. "Optimal Duration of Adjuvant Targeted-immunotherapy in Patients with Initially Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Successful Conversion Therapy." The Oncologist, vol. 31, no. 4, 2026, https://doi.org/10.1093/oncolo/oyag054.
